Effects of acarbose combined with metformin on levels of glycosylated hemoglobin and serum cystatin C in patients with newly diagnosed type 2 diabetes mellitus
10.3760/cma.j.issn.1008-6706.2017.18.013
- VernacularTitle:阿卡波糖联合二甲双胍对初发2型糖尿病患者糖化血红蛋白及血清胱抑素C水平的影响
- Author:
Xianxia MA
- Keywords:
Acarbose;
Metformin;
Type 2 diabetes mellitus;
Glycosylated hemoglobin;
Serum cystatin C
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(18):2772-2776
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects of acarbose combined with metformin in the treatment of newly diagnosed type 2 diabetes mellitus and its effects on levels of glycosylated hemoglobin and serum cystatin C.Methods 76 patients with newly diagnosed type 2 diabetes mellitus were divided into observation group and control group according to the order of admission.The control group was treated with metfonnin,the observation group was treated with acarbose combined with metformin.The levels of blood glucose and serum cystatin C before and after treatment in the two groups were compared.The clinical efficacy and side effects were analyzed.Results After treatment,the total effective rate in the observation group was significantly higher than that in the control group[89.47％ (34/38) vs.63.16％ (24/38)] (x2 =7.280,P ＜ 0.05).After treatment,the levels of glycosylated hemoglobin,postprandial blood glucose,fasting blood glucose and serum cystatin C in the observation group were significantly lower than those in the control group[(6.78 ±0.81)％,(7.01 ±0.22)mmol/L,(5.12 ±0.32)mmol/L,(0.82 ±0.11)mg/L vs.(7.99 ±0.85) ％,(9.49 ± 0.61) mmol/L,(7.32 ± 0.54) mmol/L,(1.41 ± 0.22) mg/L] (t =6.353,23.576,21.606,14.787,all P ＜ 0.05).There was no significant difference in the incidence rate of adverse reaction between the observation group and the control group [15.79％ (6/38) vs.13.16％ (5/38)] (x2 =0.106,P ＞ 0.05).Conclusion Acarbose combined with metformin can effectively reduce the levels of glycated hemoglobin and serum cystatin C in patients with newly diagnosed type 2 diabetes mellitus.The clinical efficacy is good and the adverse reaction rate is low.
